These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34994577)

  • 1. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
    Cohen JA; Bermel RA; Grossman CI; Hersh CM; Hyland M; Mowry EM; Naismith R; Naylor ML; Nicholas J; Rajbhandar R; Singh CM; Tintorè M; Zabalza A; Ziemssen T; Williams JR; Montalban X
    Mult Scler; 2022 Jun; 28(7):1131-1137. PubMed ID: 34994577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
    Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
    Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
    Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
    EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders.
    Algu P; Hameed N; DeAngelis T; Stern J; Harel A
    Mult Scler Relat Disord; 2023 Nov; 79():104965. PubMed ID: 37657307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
    Wu X; Wang L; Shen L; Tang K
    EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
    Zabalza A; Arrambide G; Otero-Romero S; Pappolla A; Tagliani P; López-Maza S; Cárdenas-Robledo S; Esperalba J; Fernández-Naval C; Martínez-Gallo M; Castillo M; Bonastre M; Resina-Salles M; Bertran J; Rodriguez-Barranco M; Carbonell-Mirabent P; Gonzalez M; Merchan M; Quiroga-Varela A; Miguela A; Gómez I; Álvarez G; Robles R; Perez Del Campo D; Queralt X; Soler MJ; Agraz I; Martinez-Valle F; Rodríguez-Acevedo B; Midaglia L; Vidal-Jordana Á; Cobo-Calvo Á; Tur C; Galan I; Castillo J; Río J; Espejo C; Comabella M; Nos C; Sastre-Garriga J; Ramió-Torrentà L; Tintoré M; Montalban X
    Mult Scler; 2022 Jun; 28(7):1138-1145. PubMed ID: 35475363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
    Proschmann U; Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dillenseger A; Dunsche M; Atta Y; Ziemssen T; Akgün K
    Mult Scler; 2023 Dec; 29(14):1849-1859. PubMed ID: 37776101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis.
    Kanakura M; Kihara K; Kinoshita M; Sugimoto T; Murata H; Beppu S; Shiraishi N; Sugiyama Y; Koda T; Takahashi MP; Chinen I; Okuno T; Mochizuki H
    Clin Neurol Neurosurg; 2024 Aug; 243():108378. PubMed ID: 38901377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
    Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
    Meyer-Arndt L; Braun J; Fauchere F; Vanshylla K; Loyal L; Henze L; Kruse B; Dingeldey M; Jürchott K; Mangold M; Maraj A; Braginets A; Böttcher C; Nitsche A; de la Rosa K; Ratswohl C; Sawitzki B; Holenya P; Reimer U; Sander LE; Klein F; Paul F; Bellmann-Strobl J; Thiel A; Giesecke-Thiel C
    J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):960-971. PubMed ID: 35835468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
    Capone F; Lucchini M; Ferraro E; Bianco A; Rossi M; Cicia A; Cortese A; Cruciani A; De Arcangelis V; De Giglio L; Motolese F; Sancetta B; Mirabella M; Di Lazzaro V
    Neurotherapeutics; 2022 Jan; 19(1):325-333. PubMed ID: 34859382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
    Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.
    Bsteh G; Hegen H; Traxler G; Krajnc N; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T
    Eur J Neurol; 2022 May; 29(5):1538-1544. PubMed ID: 35102646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables.
    Barone S; Palmieri C; Gallelli L; Rania V; Pascarella A; Abatino A; Bruno PA; Casarella A; Pasquale M; Manzo L; De Sarro G; Gambardella A; Valentino P
    Neurotherapeutics; 2024 Mar; 21(2):e00307. PubMed ID: 38237381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study.
    Conte WL
    Mult Scler Relat Disord; 2022 Jan; 57():103413. PubMed ID: 35158480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
    Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.